News

Laura Mondragón

Researchers at the Josep Carreras Institute will study a rare T-cell lymphoma thanks to the Leukemia Research Foundation

Dr. Laura Mondragón, “T-cell lymphoma” group leader at the Josep Carreras Leukaemia Research Institute, has been granted a new project to fight against angioimmunoblastic T cell lymphoma (AITL). The project, starting October 1st 2022, is funded by the Leukemia Research Foundation based in Northfield, Illinois (USA) and aims to exploit the latest generation of animal models for AITL, to better understand this type of adult lymphoma and open the door to new therapeutic approaches.

Read more
Dr. Esteller & Dra. Pujol (IDIBELL)

Discovered epigenetic alterations associated with the COVID-19 related severe inflammatory syndrome in childhood

Researchers from the Cancer Epigenetics group led by Dr. Manel Esteller at the Josep Carreras Leukaemia Research Institute and Dr. Aurora Pujol, from the Bellvitge Biomedical Research Institute, have identified an epigenetic signature associated to the development of the Multisystem Inflammatory Syndrome in Children (MIS-C) after a SARS-CoV-2 virus infection. The signature has been named EPIMISC, in line with previous studies on the epigenetics of COVID-19 from the same team.

Read more
David Corujo

Cancer vs. the immune system: macroH2A, a chromatin protein, can turn cancer cells deaf to immune commands

Researchers from the Buschbeck lab and IGTP are pushing forward our understanding of the role of the macroH2A histone variants in the progression of cancer and the crosstalk of cancer cells with the immune system. In a research paper recently published at the journal Cell Reports, the team identified two different areas where macroH2As can act when cancer cells are exposed to cytokines, the immune signaling machinery: chromatin regulation of gene expression and autocrine signaling secretion.

Read more
Francesc Solé 2022

Genetic information from myelodysplastic syndromes’ patients incorporated in the latest update of the international standard risk assessment metric: the IPSS-M

Researchers from the Josep Carreras Leukaemia Research Institute, Dr. Francesc Solé and Dr. Laura Palomo from the Myelodysplastic Syndromes Group, and Dr. Lurdes Zamora from the Myeloid Neoplasms Group, participated in the international consortium that developed the new molecular-based prognostic index for Myelodysplastic Syndromes, the IPSS-M. This new tool, recently published at NEJM Evidence, a new journal from the New England Journal of Medicine Publishing Group, will allow a better risk stratification of patients and, thus, a better treatment, tailored to their individual needs.

Read more
Graupera paper miransertib

A new fast and reliable experimental model for vascular malformations leads to the identification of miransertib as a promising therapy option

A team of researchers led by Dr. Sandra Castillo and Dr. Mariona Graupera, from the Josep Carreras Leukaemia Research Institute and member of the CIBERONC, have found the AKT inhibitor miransertib could be a new molecular treatment effective against low-flow vascular malformations, a long-awaited milestone. Their results, published at the journal EMBO Molecular Medicine, are based on a new in vivo model of blood vessels growth (angiogenesis) that could become the gold standard for this kind of studies in the short term.

Read more
Manel Esteller & Alberto Bueno 2

A mechanism is found explaining how cancer cells turn into normal harmless ones

A new research​​ describes how highly proliferative leukemia cells end up becoming normal cells that no longer multiply, by changing the chemical modifications -the so-called epigenetics- of a type of its genetic material: the messenger RNA. The article, published in the high-impact journal Leukemia, is authored by Alberto Bueno-Costa, researcher at the group of Dr. Manel Esteller, supervisor of the research and Director of the Josep Carreras Leukaemia Research Institute, ICREA Researcher and Professor at the University of Barcelona.

Read more
Damiana Álvarez-Errico

In vitro myelopoiesis from iPSCs resembles human early blood formation and opens the door to new therapeutic opportunities for cancer and inflammatory diseases

A team coordinated by the Wellcome Sanger Institute and the Josep Carreras Leukaemia Research Institute has generated a robust molecular map of the differentiation of human induced pluripotent stem cells (iPSC) into macrophages, which faithfully recapitulates the early stages of myeloid differentiation. This roadmap of early myeloid differentiation represents an essential step towards better understanding the initial stages of hematopoiesis, which are largely unexplored in humans, and will open up new cell-based therapeutic opportunities.

Read more